CN105682676A - 利用肝细胞生长因子的两种以上的异构体的肌萎缩性侧索硬化症预防或治疗用组合物 - Google Patents
利用肝细胞生长因子的两种以上的异构体的肌萎缩性侧索硬化症预防或治疗用组合物 Download PDFInfo
- Publication number
- CN105682676A CN105682676A CN201480058075.3A CN201480058075A CN105682676A CN 105682676 A CN105682676 A CN 105682676A CN 201480058075 A CN201480058075 A CN 201480058075A CN 105682676 A CN105682676 A CN 105682676A
- Authority
- CN
- China
- Prior art keywords
- growth factor
- hepatocyte growth
- sequence
- pck
- lateral sclerosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 title claims abstract description 82
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 title claims abstract description 82
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 title claims abstract description 60
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 108010029485 Protein Isoforms Proteins 0.000 title abstract description 4
- 102000001708 Protein Isoforms Human genes 0.000 title abstract description 4
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 43
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 43
- 239000002157 polynucleotide Substances 0.000 claims abstract description 43
- 108090000623 proteins and genes Proteins 0.000 claims description 52
- 239000002773 nucleotide Substances 0.000 claims description 50
- 125000003729 nucleotide group Chemical group 0.000 claims description 50
- 230000002265 prevention Effects 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 23
- 230000007547 defect Effects 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 14
- 239000013612 plasmid Substances 0.000 claims description 13
- 102000053602 DNA Human genes 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- 108020004414 DNA Proteins 0.000 claims description 7
- 239000004615 ingredient Substances 0.000 claims description 7
- 108091061960 Naked DNA Proteins 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 85
- 239000003102 growth factor Substances 0.000 description 77
- 238000000034 method Methods 0.000 description 42
- 230000008569 process Effects 0.000 description 29
- 241000699666 Mus <mouse, genus> Species 0.000 description 25
- 230000006907 apoptotic process Effects 0.000 description 25
- 230000012010 growth Effects 0.000 description 25
- 230000033001 locomotion Effects 0.000 description 23
- 108020004635 Complementary DNA Proteins 0.000 description 22
- 238000010804 cDNA synthesis Methods 0.000 description 22
- 239000002299 complementary DNA Substances 0.000 description 22
- 210000003494 hepatocyte Anatomy 0.000 description 20
- 239000006228 supernatant Substances 0.000 description 20
- 108700024394 Exon Proteins 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 19
- 230000010261 cell growth Effects 0.000 description 17
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 15
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 14
- 150000001413 amino acids Chemical group 0.000 description 14
- 239000001963 growth medium Substances 0.000 description 14
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 239000012091 fetal bovine serum Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 241000701161 unidentified adenovirus Species 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 description 11
- 230000005540 biological transmission Effects 0.000 description 11
- 241000700605 Viruses Species 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000012545 processing Methods 0.000 description 10
- 238000001890 transfection Methods 0.000 description 10
- 230000001939 inductive effect Effects 0.000 description 9
- 230000035800 maturation Effects 0.000 description 8
- 230000001537 neural effect Effects 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000009331 sowing Methods 0.000 description 8
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 7
- 230000036542 oxidative stress Effects 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 238000003753 real-time PCR Methods 0.000 description 7
- 239000013603 viral vector Substances 0.000 description 7
- 241000702421 Dependoparvovirus Species 0.000 description 6
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 6
- 102000019197 Superoxide Dismutase Human genes 0.000 description 6
- 108010012715 Superoxide dismutase Proteins 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000001476 gene delivery Methods 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 229960004181 riluzole Drugs 0.000 description 6
- 229920002477 rna polymer Polymers 0.000 description 6
- 206010020880 Hypertrophy Diseases 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000001177 retroviral effect Effects 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 3
- 108010014173 Factor X Proteins 0.000 description 3
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 3
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- 101150024147 bax gene Proteins 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940012426 factor x Drugs 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 2
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 2
- 241001135569 Human adenovirus 5 Species 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 2
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 108700041737 bcl-2 Genes Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000003365 immunocytochemistry Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- GQMMRLBWXCGBEV-YVMONPNESA-N (nz)-n-[(3-nitrophenyl)methylidene]hydroxylamine Chemical compound O\N=C/C1=CC=CC([N+]([O-])=O)=C1 GQMMRLBWXCGBEV-YVMONPNESA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000006734 Beta-Globulins Human genes 0.000 description 1
- 108010087504 Beta-Globulins Proteins 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 102100031939 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 1
- 101000664887 Homo sapiens Superoxide dismutase [Cu-Zn] Proteins 0.000 description 1
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 241001561899 Otomys Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101710089165 Protein white Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 238000010818 SYBR green PCR Master Mix Methods 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000012578 cell culture reagent Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Natural products NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- -1 cytosine arabinosides Chemical class 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 101150030339 env gene Proteins 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 101150098622 gag gene Proteins 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 102000054767 gene variant Human genes 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 102000057308 human HGF Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 101150088264 pol gene Proteins 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Psychiatry (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (12)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130126216 | 2013-10-22 | ||
KR10-2013-0126216 | 2013-10-22 | ||
PCT/KR2014/009971 WO2015060650A2 (ko) | 2013-10-22 | 2014-10-22 | 간세포 성장인자의 둘 이상의 이형체를 이용한 근위축성 측삭 경화증 예방 또는 치료용 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105682676A true CN105682676A (zh) | 2016-06-15 |
CN105682676B CN105682676B (zh) | 2020-10-23 |
Family
ID=53386224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201480058075.3A Active CN105682676B (zh) | 2013-10-22 | 2014-10-22 | 利用肝细胞生长因子的两种以上的异构体的肌萎缩性侧索硬化症预防或治疗用组合物 |
Country Status (13)
Country | Link |
---|---|
US (1) | US10639351B2 (zh) |
EP (1) | EP3061457B1 (zh) |
JP (1) | JP6240337B2 (zh) |
KR (2) | KR101779775B1 (zh) |
CN (1) | CN105682676B (zh) |
AU (1) | AU2014337870B2 (zh) |
BR (1) | BR112016008267A2 (zh) |
CA (1) | CA2926607C (zh) |
ES (1) | ES2773305T3 (zh) |
HK (1) | HK1219873A1 (zh) |
MX (1) | MX2016005006A (zh) |
RU (1) | RU2639582C2 (zh) |
SG (1) | SG11201602452SA (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110577954A (zh) * | 2019-10-12 | 2019-12-17 | 北京万福来生物技术有限责任公司 | 突变的肝细胞生长因子基因及其应用 |
CN111542613A (zh) * | 2017-12-29 | 2020-08-14 | 赫利世弥斯株式会社 | 导入有杂交的肝细胞生长因子的腺相关病毒载体 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3046202B1 (fr) * | 2015-12-24 | 2017-12-29 | Snecma | Turboreacteur avec un moyen de reprise de poussee sur le carter inter-compresseurs |
US20200024323A1 (en) * | 2018-07-17 | 2020-01-23 | Helixmith Co., Ltd. | Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0255320A3 (en) | 1986-07-28 | 1989-09-06 | Genzyme Corporation | Production of proteins in myeloma cells |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
NZ232813A (en) | 1989-03-10 | 1992-08-26 | Snow Brand Milk Products Co Ltd | Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons |
US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
CA2022752C (en) | 1989-08-11 | 1998-07-07 | Naomi Kitamura | Hepatic parenchymal cell growth factor, gene encoding the same, process for producing the factor, and transformants producing the factor |
US6706694B1 (en) | 1990-03-21 | 2004-03-16 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate |
EP0539590B1 (en) | 1990-07-13 | 1999-03-31 | Snow Brand Milk Products Co., Ltd. | Plasmid containing dna which codes for the amino acid sequence of tcf-ii, transformed cell, and production of physiologically active substance by using the same |
US5661133B1 (en) | 1991-11-12 | 1999-06-01 | Univ Michigan | Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein |
US7323297B1 (en) | 1992-04-03 | 2008-01-29 | The Regents Of The University Of California | Stabilized polynucleotide complexes and methods |
JP3680114B2 (ja) | 1993-09-17 | 2005-08-10 | 敏一 中村 | 脳神経障害治療剤 |
US5837676A (en) | 1993-10-18 | 1998-11-17 | Long Island Jewish Medical Center | Use of scatter factor to enhance angiogenesis |
US6498144B1 (en) | 1993-10-18 | 2002-12-24 | North Shore - Long Island Jewish Research Institute | Use of scatter factor to enhance angiogenesis |
US5652225A (en) | 1994-10-04 | 1997-07-29 | St. Elizabeth's Medical Center Of Boston, Inc. | Methods and products for nucleic acid delivery |
US6143714A (en) | 1994-10-24 | 2000-11-07 | Regeneron Pharmaceuticals, Inc. | Methods of using hepatocyte growth factor to promote survival, growth and differentiation of motor neurons |
US20030148968A1 (en) | 1995-02-28 | 2003-08-07 | Hammond H. Kirk | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
JP3927248B2 (ja) | 1995-07-11 | 2007-06-06 | 第一製薬株式会社 | Hgf凍結乾燥製剤 |
KR100725199B1 (ko) | 1995-08-29 | 2007-08-16 | 안제스에무지 가부시키가이샤 | 에이치지에프유전자를함유하는약제 |
US5830879A (en) | 1995-10-02 | 1998-11-03 | St. Elizabeth's Medical Center Of Boston, Inc. | Treatment of vascular injury using vascular endothelial growth factor |
US6121246A (en) | 1995-10-20 | 2000-09-19 | St. Elizabeth's Medical Center Of Boston, Inc. | Method for treating ischemic tissue |
CA2289600C (en) | 1997-05-06 | 2010-06-29 | The Regents Of The University Of California | Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes |
WO1999036103A1 (en) | 1998-01-16 | 1999-07-22 | Mcgill University | Prevention and treatment of neuropathy by hepatocyte growth factor |
JPH11246433A (ja) | 1998-03-03 | 1999-09-14 | Sumitomo Pharmaceut Co Ltd | 心筋梗塞治療剤 |
US20040228834A1 (en) | 1998-03-09 | 2004-11-18 | Jeffrey Isner | Compositions and methods for modulating vascularization |
AU766238B2 (en) | 1998-03-09 | 2003-10-09 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Compositions and methods for modulating vascularization |
US7276359B1 (en) | 1998-03-13 | 2007-10-02 | Wyeth | Polynucleotide composition, method of preparation, and use thereof |
EP1555033A3 (en) | 1998-03-13 | 2005-08-17 | Wyeth | Polynucleotide composition, method of preparation, and use thereof |
WO1999045966A1 (en) | 1998-03-13 | 1999-09-16 | American Home Products Corporation | Polynucleotide composition, method of preparation, and use thereof |
CN1222310C (zh) | 1998-08-05 | 2005-10-12 | 住友制药株式会社 | 肝实质细胞增殖因子药用制剂 |
KR20000046969A (ko) | 1998-12-31 | 2000-07-25 | 이선경 | 이종 유전자 유래의 유전자 발현 조절요소를 포함하는 강력한전사 활성을 가진 진핵세포 발현벡더 |
PT1142590E (pt) | 1999-10-29 | 2008-10-27 | Anges Mg Inc | Terapêutica génica para doença isquémica diabética |
KR20020049031A (ko) | 1999-11-05 | 2002-06-24 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 생체내 유전자 송달에 의하여 심혈관 질환을 치료하기위한 기술 및 조성물 |
KR100798566B1 (ko) | 2000-06-27 | 2008-01-28 | 안제스에무지 가부시키가이샤 | 혈관 신생요법용 의약조성물 |
RU2311921C2 (ru) | 2000-09-13 | 2007-12-10 | Чугаи Сейяку Кабусики Кайся | Лекарственные средства для лечения ишемических заболеваний |
US20030176347A1 (en) * | 2003-05-14 | 2003-09-18 | Toshikazu Nakamura | Remedies for amyotrophic lateral sclerosis |
JP5442173B2 (ja) | 2000-09-14 | 2014-03-12 | 敏一 中村 | 筋萎縮性側索硬化症治療剤 |
CN1150035C (zh) | 2000-12-21 | 2004-05-19 | 中国人民解放军军事医学科学院放射医学研究所 | 一种重组质粒及其在疾病防治中的应用 |
US20020172663A1 (en) | 2001-01-23 | 2002-11-21 | Maria Palasis | Localized myocardial injection method for treating ischemic myocardium |
KR100562824B1 (ko) | 2002-03-20 | 2006-03-23 | 주식회사 바이로메드 | 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자 |
US20140170116A9 (en) | 2002-08-22 | 2014-06-19 | Marc S. Penn | Method of treating ischemic disorders |
EP1578193A4 (en) | 2002-12-23 | 2011-06-15 | Vical Inc | FREEZING PROCESS FOR NUCLEIC ACID / BLOCK COPOLYMER / CATION SIDE COMPLEXES |
US20050164208A1 (en) | 2004-01-22 | 2005-07-28 | Paul Poulin | Storage of genetic information |
KR100833612B1 (ko) | 2004-12-29 | 2008-05-30 | 에프씨비파미셀 주식회사 | 간엽 간세포로부터 분화된 신경세포를 유효성분으로함유하는 신경계 질환 치료용 약학 조성물 |
EP1865992A2 (en) | 2005-03-31 | 2007-12-19 | Mytogen Inc. | Treatment for heart disease |
US20070212390A1 (en) | 2005-09-22 | 2007-09-13 | Ludwig Institute For Cancer Research | Protease-resistant forms of VEGF-D, method of making and method of use |
BRPI0618488A2 (pt) | 2005-11-10 | 2011-08-30 | Receptor Biologix Inc | proteìnas de fusão de ìntron de fator de crescimento de hepatócito |
EP2022853A4 (en) | 2006-05-17 | 2010-03-10 | Yoshiyuki Koyama | FREEZERED PRODUCT FOR THE TRANSFER OF NUCLEIC ACID, OLIGONUCLEIC ACID OR DERIVATIVES THEREOF |
WO2007142651A1 (en) | 2006-06-09 | 2007-12-13 | Caritas St. Elizabeth Medical Center Of Boston, Inc. | Methods and compositions for the treatment of neuropathy |
WO2009060608A1 (ja) | 2007-11-07 | 2009-05-14 | Ono Pharmaceutical Co., Ltd. | Sdf-1を含有してなる徐放性組成物 |
US20090202606A1 (en) | 2008-01-25 | 2009-08-13 | Viromed Co., Ltd. | Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor |
ES2556711T3 (es) | 2008-04-09 | 2016-01-19 | Viromed Co., Ltd. | Formulaciones liofilizadas de ADN para el aumento de la expresión del ADN plasmídico |
RU2413524C1 (ru) | 2009-07-31 | 2011-03-10 | Общество с ограниченной ответственностью "КриоЦентр" | Способ лечения психических и неврологических расстройств |
WO2011079261A2 (en) | 2009-12-23 | 2011-06-30 | Curna, Inc. | Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf |
WO2012025925A1 (en) | 2010-08-24 | 2012-03-01 | Rappaport Family Institute For Research In The Medical Sciences | Methods of improving transplantation using sdf-1alpha |
WO2013037521A1 (en) | 2011-09-16 | 2013-03-21 | Medical Research Council | Modified hgf-1k1 polypeptide |
WO2013037520A1 (en) | 2011-09-16 | 2013-03-21 | Glaxo Group Limited | Modified hgf-1k1 polypeptide |
JP2013129661A (ja) * | 2013-02-20 | 2013-07-04 | Toshiichi Nakamura | 筋萎縮性側索硬化症治療剤 |
-
2014
- 2014-10-22 ES ES14856385T patent/ES2773305T3/es active Active
- 2014-10-22 CN CN201480058075.3A patent/CN105682676B/zh active Active
- 2014-10-22 EP EP14856385.1A patent/EP3061457B1/en active Active
- 2014-10-22 KR KR1020140143377A patent/KR101779775B1/ko active IP Right Grant
- 2014-10-22 MX MX2016005006A patent/MX2016005006A/es active IP Right Grant
- 2014-10-22 US US15/030,999 patent/US10639351B2/en active Active
- 2014-10-22 AU AU2014337870A patent/AU2014337870B2/en active Active
- 2014-10-22 RU RU2016119116A patent/RU2639582C2/ru active
- 2014-10-22 BR BR112016008267A patent/BR112016008267A2/pt not_active Application Discontinuation
- 2014-10-22 CA CA2926607A patent/CA2926607C/en active Active
- 2014-10-22 JP JP2016546724A patent/JP6240337B2/ja active Active
- 2014-10-22 SG SG11201602452SA patent/SG11201602452SA/en unknown
-
2016
- 2016-07-06 HK HK16107864.0A patent/HK1219873A1/zh unknown
-
2017
- 2017-08-31 KR KR1020170110892A patent/KR101860452B1/ko active IP Right Grant
Non-Patent Citations (8)
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111542613A (zh) * | 2017-12-29 | 2020-08-14 | 赫利世弥斯株式会社 | 导入有杂交的肝细胞生长因子的腺相关病毒载体 |
CN111542613B (zh) * | 2017-12-29 | 2023-11-21 | 赫利世弥斯株式会社 | 导入有杂交的肝细胞生长因子的腺相关病毒载体 |
CN110577954A (zh) * | 2019-10-12 | 2019-12-17 | 北京万福来生物技术有限责任公司 | 突变的肝细胞生长因子基因及其应用 |
Also Published As
Publication number | Publication date |
---|---|
JP2016534149A (ja) | 2016-11-04 |
MX2016005006A (es) | 2016-07-14 |
US20160250291A1 (en) | 2016-09-01 |
RU2016119116A (ru) | 2017-11-28 |
CA2926607C (en) | 2018-10-23 |
EP3061457A2 (en) | 2016-08-31 |
JP6240337B2 (ja) | 2017-11-29 |
AU2014337870B2 (en) | 2019-11-28 |
KR20150047108A (ko) | 2015-05-04 |
KR101779775B1 (ko) | 2017-09-21 |
KR101860452B1 (ko) | 2018-05-24 |
HK1219873A1 (zh) | 2017-04-21 |
US10639351B2 (en) | 2020-05-05 |
BR112016008267A2 (pt) | 2017-10-03 |
AU2014337870A1 (en) | 2016-05-05 |
ES2773305T3 (es) | 2020-07-10 |
RU2639582C2 (ru) | 2017-12-21 |
KR20170104129A (ko) | 2017-09-14 |
EP3061457B1 (en) | 2020-01-22 |
SG11201602452SA (en) | 2016-05-30 |
CA2926607A1 (en) | 2015-04-30 |
EP3061457A4 (en) | 2017-06-07 |
CN105682676B (zh) | 2020-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Paterna et al. | Influence of promoter and WHV post-transcriptional regulatory element on AAV-mediated transgene expression in the rat brain | |
JP2019506445A (ja) | パルボウイルスベクターの高められた送達のための改変キャプシドタンパク質 | |
JP2024069591A (ja) | 操作されたdna結合タンパク質 | |
US11535870B2 (en) | Adeno-associated virus vectors encoding modified G6PC and uses thereof | |
JP2016517278A (ja) | スタッファー/フィラーポリヌクレオチド配列を含むベクターおよびその使用方法 | |
Liu et al. | Promoter effects of adeno-associated viral vector for transgene expression in the cochlea in vivo | |
US10759841B2 (en) | Gene therapy for diabetic neuropathy using an HGF isoform | |
TW201629225A (zh) | 第九因子基因療法 | |
CN105682676A (zh) | 利用肝细胞生长因子的两种以上的异构体的肌萎缩性侧索硬化症预防或治疗用组合物 | |
Kaemmerer et al. | In vivo transduction of cerebellar Purkinje cells using adeno-associated virus vectors | |
KR20210131370A (ko) | Grn-연관 성인-발병 신경퇴화의 치료를 위한 재조합 아데노-연관 바이러스 | |
KR20230058102A (ko) | Grn 관련 성인 발병 신경변성 치료를 위한 재조합 아데노-연관 바이러스 | |
CA3090226A1 (en) | Adeno-associated virus compositions for restoring pah gene function and methods of use thereof | |
KR20230038503A (ko) | 샤르코-마리-투스 질환의 치료에 유용한 조성물 | |
CN114127296A (zh) | Ube3a基因和表达盒及其应用 | |
EP2558113B1 (en) | Serca2 therapeutic compositions and methods of use | |
EP3199182A1 (en) | Composition for preventing or treating peripheral vascular disease using hepatocyte growth factor and stromal cell derived factor 1 | |
WO2024125494A1 (zh) | 一种基因调节的方法及其应用 | |
US20240148830A1 (en) | Treatment of Neurological Disorder Using NHR | |
WO2015060650A2 (ko) | 간세포 성장인자의 둘 이상의 이형체를 이용한 근위축성 측삭 경화증 예방 또는 치료용 조성물 | |
TW202402329A (zh) | Irak4調節劑於基因療法之用途(二) | |
JP2022506066A (ja) | 最適化されたfig4遺伝子および発現カセットならびにそれらの使用 | |
Lewis | Development of an adenoviral vector platform for selective gene delivery to neurons |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1219873 Country of ref document: HK |
|
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: Seoul, South Kerean Applicant after: Hellis Messi Co., Ltd. Address before: Seoul, South Kerean Applicant before: Viromed Co., Ltd. |
|
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: Han Guo Shouer Applicant after: Helismith Corporation Address before: Han Guo Shouer Applicant before: Hellis Messi Co., Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |